Fisher & Paykel Healthcare Corporation Limited revised earnings guidance for the financial year ending 31 March 2024. The full year guidance previously provided on 29 November 2023, based on a NZ:US exchange rate of 58 cents, was for operating revenue to be approximately $1.7 billion and net profit after tax to be in the range of approximately $250 million to $260 million. Now, assuming a NZ:US exchange rate of approximately 61 cents for the balance of the financial year, the company expects full year operating revenue to be approximately $1.73 billion and underlying profit after tax (excluding any fair value changes) to be in the range of approximately $260 million to $265 million.
Fisher & Paykel Healthcare Corporation Limited
Equities
FPH
NZFAPE0001S2
Medical Equipment, Supplies & Distribution
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
28.85 NZD | -0.21% | +0.63% | +22.25% |
Apr. 09 | New Zealand Shares Fall for Second Day; Fisher & Paykel Healthcare Launches Apnea Mask | MT |
Apr. 09 | Fisher & Paykel Begins Selling Lightest Mask for Sleep Apnea | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.25% | 10.3B | |
-6.36% | 180B | |
+3.03% | 112B | |
-2.92% | 68.53B | |
+5.40% | 51.97B | |
+6.57% | 44.08B | |
+5.62% | 42.23B | |
+23.60% | 32.43B | |
+16.72% | 26.39B | |
-3.25% | 24.97B |
- Stock Market
- Equities
- FPH Stock
- News Fisher & Paykel Healthcare Corporation Limited
- Fisher & Paykel Healthcare Corporation Limited Revises Earnings Guidance for the Financial Year Ending 31 March 2024